NYR Shares Nyrada Inc.
WATCH ASX · ASXCardiovascular and brain-injury programs provide multiple clinical catalysts and financing visibility.
Signal breakdown
- ▸Positive cash position and PROTECT-MI clinical update.
- ▾Below 50-day MA (-20.62%)
- ▾Near 52-week low (9.1% of range)
Is NYR a buy right now?
Trend: NYR is trading below the 50-day average (-20.49%), RSI 27 — oversold territory, with a 3-month return of -12.61%.
Valuation & quality: Nyrada Inc. trades on price-to-book 12.44; fundamentals show net margin 0.0%, return on equity -100.0%, revenue growth -23.0% year on year.
Our screen: WATCH (score 0) — Cardiovascular and brain-injury programs provide multiple clinical catalysts and financing visibility.
Computed from end-of-day data; not personal advice.
Our track record with NYR
First flagged in our daily picks as WATCH on 2026-10-27 at $0.49.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.00% | -13.10% | -5.70% | -10.00% | +42.20% | +29.70% | -39.80% | -2.00% |
Fundamentals
Technical signals
About Nyrada Inc.
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.